Literature DB >> 18575766

Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors.

Karina Dahl Steffensen1, Marianne Waldstrøm, Rikke Fredslund Andersen, Dorte Aalund Olsen, Ulla Jeppesen, Hans Jørgen Knudsen, Ivan Brandslund, Anders Jakobsen.   

Abstract

The epidermal growth factor receptors, HER1, HER2, HER3 and HER4 play a key role in the growth of malignant tumors. The receptors of the EGF receptor family are not cancer-specific proteins since these receptors are expressed to some extent in both normal and benign tissue, but this is not elucidated in detail in ovarian tissue. High tumor-to-normal-tissue concentration ratios would be favorable for molecular targeted anti-cancer treatment. The primary aim of the study was to analyze the potential differential protein content and gene expression of the four receptors in benign and malignant ovarian tumors. Tissue from 207 patients (101 malignant, 19 borderline, 64 benign ovarian tumors and 23 normal ovaries) were analyzed by quantitative ELISA for HER1-HER4 protein concentrations and by real-time PCR for HER1-HER4 gene expression. HER2 was also analyzed by immunohistochemistry. The HER2-4 receptor protein content and the median gene expression level was significantly higher in ovarian cancer patients compared to patients with benign ovarian tumors and normal ovaries (p<0.0000001). The protein content of the HER1 receptor was significantly lower in ovarian cancer compared to borderline tumors (p=0.012), benign ovarian tumors (p=0.049) and to normal ovaries (p=0.000069). A sound correlation between the protein levels and gene expressions was documented. In conclusion, decreased concentration of HER1 protein and increased HER2, HER3 and HER4 protein concentration were observed, as also elevated HER2-HER4 gene expression levels in ovarian cancer patients with barely any overlap of the HER3 and HER4 expression in malignant ovarian tumors compared to benign ovarian tissues.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18575766

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  14 in total

1.  HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.

Authors:  Marcia R Campbell; Dhara Amin; Mark M Moasser
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

2.  Reactive oxygen species regulate ERBB2 and ERBB3 expression via miR-199a/125b and DNA methylation.

Authors:  Jun He; Qing Xu; Yi Jing; Faton Agani; Xu Qian; Richard Carpenter; Qi Li; Xin-Ru Wang; Stephen S Peiper; Zhimin Lu; Ling-Zhi Liu; Bing-Hua Jiang
Journal:  EMBO Rep       Date:  2012-11-13       Impact factor: 8.807

3.  Biomarkers and endosalpingiosis in the ovarian and tubal microenvironment of women at high-risk for pelvic serous carcinoma.

Authors:  Christine Gruessner; Angelika Gruessner; Katherine Glaser; Nisreen Abushahin; Cynthia Laughren; Wenxin Zheng; Setsuko K Chambers
Journal:  Am J Cancer Res       Date:  2014-01-15       Impact factor: 6.166

4.  Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.

Authors:  Ulrike Unger; Carsten Denkert; Ioana Braicu; Jalid Sehouli; Manfred Dietel; Sibylle Loibl; Silvia Darb-Esfahani
Journal:  Virchows Arch       Date:  2016-12-02       Impact factor: 4.064

5.  Systematic analysis and molecular profiling of EGFR allosteric inhibitor cross-reactivity across the proto-oncogenic ErbB family kinases by integrating dynamics simulation, energetics calculation and biochemical assay.

Authors:  Yanli Ma; Bingli Qi; Meiying Ning; Lijuan Zhang; Zeyu An; Jing Zhao
Journal:  Eur Biophys J       Date:  2022-03-21       Impact factor: 1.733

6.  Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells.

Authors:  Peter W Schlosshauer; Wei Li; Kai-Ti Lin; Joseph L-K Chan; Lu-Hai Wang
Journal:  Gynecol Oncol       Date:  2009-07-02       Impact factor: 5.482

7.  MicroRNAs related polymorphisms and genetic susceptibility to esophageal squamous cell carcinoma.

Authors:  Yanhong Qu; Honghong Qu; Manli Luo; Peng Wang; Chunhua Song; Kaijuan Wang; Jianying Zhang; Liping Dai
Journal:  Mol Genet Genomics       Date:  2014-06-12       Impact factor: 3.291

8.  EGF-induced EMT and invasiveness in serous borderline ovarian tumor cells: a possible step in the transition to low-grade serous carcinoma cells?

Authors:  Jung-Chien Cheng; Nelly Auersperg; Peter C K Leung
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240

Review 9.  The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer.

Authors:  Q Sheng; J Liu
Journal:  Br J Cancer       Date:  2011-03-01       Impact factor: 7.640

10.  Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.

Authors:  Doris R Siwak; Mark Carey; Bryan T Hennessy; Catherine T Nguyen; Mollianne J McGahren Murray; Laura Nolden; Gordon B Mills
Journal:  J Oncol       Date:  2009-11-19       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.